Cargando…

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

BACKGROUND: SB939 is an orally available, competitive histone deacetylase (HDAC) inhibitor selective for class I, II and IV histone deacetylases. Preclinical evaluation of SB939 revealed a profile suggesting improved efficacy compared to other HDAC inhibitors. This phase I study was carried out to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048208/
https://www.ncbi.nlm.nih.gov/pubmed/21285985
http://dx.doi.org/10.1038/bjc.2011.13